Skip to main content

BIOMARCADORES Y PERFILES CLINICOS DIFERENCIADOS EN FASES PRECOCES DE LA ENFERMEDAS PULMONAR OBSTRUCTIVA CRONICA (BIOEARLY-COPD)

PI21/00785

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Execution centre INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COPD, systemic proteomic profiles in frequent and infrequent exacerbators

  • Enríquez-Rodríguez, César Jessé|||0000-0002-5944-6555
  • Casadevall, Carme|||0000-0001-6458-8972
  • Faner, Rosa|||0000-0002-8159-0115
  • Castro Acosta, Ady|||0000-0001-7591-6011
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Seijó, Luis|||0000-0001-9344-728X
  • López Campos, José Luis|||0000-0003-1703-1367
  • Peces-Barba, Germán
  • Monso, Eduard|||0000-0003-1876-3092
  • Barreiro, Esther|||0000-0003-2708-3443
  • Cosio, Borja G.|||0000-0002-6388-8209
  • Agustí García-Navarro, Àlvar|||0000-0003-3271-3788
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the systemic proteomic profile in FE versus NFE. As a reference, we also determined the systemic proteomic profile of healthy controls (HC) and COPD patients during an actual episode of exacerbation (AE). In the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), and 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins/peptides (DAPs). Compared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE. There are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE. Although COPD exacerbations are characterised by a specific plasma proteomic profile, those patients who suffer frequent acute episodes maintain some of these abnormalities, providing a possible biological basis for this phenotype.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD, A Pilot Study

  • Casadevall, Carme|||0000-0001-6458-8972
  • Quero, Sara|||0000-0002-6454-6358
  • Millares, Laura|||0000-0002-0242-0274
  • Faner, Rosa|||0000-0002-8159-0115
  • Cosio, Borja G.|||0000-0002-6388-8209
  • Peces-Barba, Germán
  • Castro Acosta, Ady|||0000-0001-7591-6011
  • Montón, Concepción
  • Palou, Alexandre
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Agustí, Àlvar
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
  • Monso, Eduard|||0000-0003-1876-3092
The respiratory microbiome may influence the development and progression of COPD by modulating local immune and inflammatory events. We aimed to investigate whether relative changes in respiratory bacterial abundance are also associated with systemic inflammation, and explore their relationship with the main clinical COPD phenotypes. Multiplex analysis of inflammatory markers and transcript eosinophil-related markers were analyzed on peripheral blood in a cohort of stable COPD patients (n = 72). Respiratory microbiome composition was analyzed by 16S rRNA microbial sequencing on spontaneous sputum. Spearman correlations were applied to test the relationship between the microbiome composition and systemic inflammation. The concentration of the plasma IL-8 showed an inverted correlation with the relative abundance of 17 bacterial genera in the whole COPD cohort. COPD patients categorized as eosinophilic showed positive relationships with blood eosinophil markers and inversely correlated with the degree of airway obstruction and the number of exacerbations during the previous year. COPD patients categorized as frequent exacerbators were enriched with the bacterial genera Pseudomonas which, in turn, was positively associated with the severity of airflow limitation and the prior year's exacerbation history. The associative relationships of the sputum microbiome with the severity of the disease emphasize the relevance of the interaction between the respiratory microbiota and systemic inflammation.